# Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

> **NCT00214773** · — · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 237 (actual)

## Conditions studied

- Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00214773
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-05-01
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00214773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00214773, "Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00214773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*